A stock in the biotechnology and drugs complex whose insiders are snapping up a decent amount of shares is United Therapeutics ( UTHR), a biotechnology company focused on the development and commercialization of products to address the unmet medical needs of patients. Insiders are buying into weakness here since the stock is off by over 30% in 2011. United Therapeutics has a market cap of $2.42 billion and an enterprise value of $2.01 billion. This stock trades at a cheap valuation; its trailing price-to-earnings is 13.87, and its forward price-to-earnings is 10.44. This is a cash-rich company, with a total cash position of $694.60 million and total debt of $317.47 million. After you back out the debt, United Therapeutics has $377.23 million in cash on their books. The CEO and director just bought 12,994 shares, or $539,178 worth of stock, at $40.98 to $42.19 per share. The same CEO also bought over $2 million worth of stock since the start of December. From a technical standpoint, UTHR is currently trading above both its 50-day and 200-day moving averages, which is bullish. This stock hit a low in October of $36.55 a share and since then it has rallied strong to its current price of just over $41.40 a share. As long as UTHR can hold above its 50-day moving average of $41.10, then the stock sets up to test a near-term breakout. If you're bullish on UTHR, I would get long once it breaks out above some overhead resistance at $42.68 and $44.96 on high-volume. Look for a high-volume move above those levels that hits near or above its three-month average action of 1,364,600 shares. If we get that action, then this stock could setup to make a run towards $50 to $52.95 (the 200-day) a share. I would simply use a mental stop that's a few percentage points below the 50-day if you get long UTHR in the near future. United Therapeutics shows up on a recent list of 5 Biotech Stocks for 2012 and was featured recently in " 5 Low-Risk Stocks to Buy for 2012."